







*1MONIRA ABD ELLATIF ABD ELKADER, 2HANAN FAROUK ALY 
1Biochemistry Department, Division of Genetic Engineering and Biotechnology, 2Therapeutic Chemistry Department, Division of 
Pharmaceutical and Drug Industries Research, National Research Centre, 33 Bohouth St., Dokki, Giza, Egypt 
Email: mkader1233@yahoo.com               
 Received: 08 Jun 2015 Revised and Accepted: 06 Jul 2015 
ABSTRACT  
Objective: Iron overload is a serious, potentially fatal disorder characterized by the deposition of excess iron within tissues leading to functional 
impairment and reduced life expectancy. The present study was designed to evaluate the efficacy of melatonin in protecting rats against iron 
overload-induced toxicity. 
Methods: Twenty-four adult male rats were randomly divided into four groups: the control, iron overload group, melatonin group and iron 
overload+melatonin group. Rats received ferric hydroxide poly maltose at a dose of 50 mg/kg body weight (three doses per week) for four weeks 
through intra peritoneal injections and received the melatonin subcutaneously (10 mg/kg/day) for four weeks. 
Results: In iron overloaded rats, the iron status markers: serum, hepatic and renal tissues iron, Total Iron Binding Capacity (TIBC), transferrin and 
transferrin saturation percentage (TS %) were significantly increased, while a marked decrease in Unsaturated Iron Binding Capacity (UIBC) was 
demonstrated. The oxidative stress marker malondialdehyde (MDA) was significantly increased while a marked decrease in the catalase (CAT) and 
glutathione peroxidase (GPx) activities as well as in reduced glutathione (GSH) content accompanied with increased levels of metallothionein (MT) 
in hepatic and renal tissues were demonstrated. In addition, the liver and kidney functions were disturbed. Co-treatment with melatonin, 
significantly improved iron overload-induced alterations as indicated by the attenuation of the iron status disturbances, the reduction of the indices 
of liver and kidney functions and lipid peroxidation product and elevation of antioxidants and MT. 
Conclusion: The study showed the potential effect of melatonin against iron overload–induced toxicity through its chelating effect on iron, elevation 
of MT and improvement of antioxidant status. 
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INTRODUCTION  
Iron is a physiologically important element that plays an essential role 
in erythropoiesis, oxygen transport, oxidative energy production and 
mitochondrial respiration [1]. Iron is found in functional forms in 
hemoglobin, myoglobin, cytochromes, enzymes with iron sulphur 
complexes and other iron-dependent enzymes [2]. Although an 
optimum level of iron is always maintained by the cells to balance 
between essentiality and toxicity, in some situations it is disrupted, 
resulting in iron overload which is associated to the oxidative stress 
induced disorders including anemia, heart failure, liver cirrhosis, 
kidney injury, fibrosis, diabetes, arthritis, depression, impotency, 
infertility and cancer [3]. Increased numbers of bacterial infections, 
reduced polymorph nuclear neutrophil function and tissue iron 
deposition were also reported [4]. However, iron-overload can 
potentiate various forms of tissue injury with oxidative stress through 
the formation of hydroxyl radicals [2] and lipid peroxidation [3].  
In all iron overload-induced diseases, iron removal by iron chelation 
therapy is an effective life-saving strategy. A large number of 
substances can chelate iron and many of them are present in 
biological systems. The proteins that participate in iron metabolism 
can sequester iron thus preventing it from participating in free 
radical reactions. Ferritin, transferrin, and several iron-containing 
enzymes such as CAT, maintain iron at a ferric or higher reduced 
state, making it less reactive to initiate and/or propagate free radical 
reactions. Several other compounds, both natural and synthetic can 
chelate iron in vivo. Although iron chelation and antioxidant abilities 
of deferoxamine suggest its clinical use, high doses result in growth 
retardation, ototoxicity and ocular toxicity as well as bone 
deformities [5]. EDTA is another synthetic, compound normally 
present in foods, that can chelate iron but it is unable to prevent iron 
mediated oxygen reduction, therefore its efficiency as an antioxidant 
is low. An antioxidant that protects from iron toxicity is a substance 
that can chelate ferrous iron and prevent the reaction with oxygen 
or peroxides; maintain iron in a redox state that makes it unable to 
reduce molecular oxygen and can trap already formed radicals [6]. 
One of the recently most studied antioxidant agents is melatonin (N-
acetyl-5 methoxy tryptamine). It is a mammalian hormone, which is 
synthesized from serotonin mainly in the pineal gland, but some is 
also synthesized in the retina, eye lens, bone marrow and 
lymphocytes. Melatonin plays a significant role in the regulation of 
many physiological events due to its efficacy as a free radical 
scavenger and indirect antioxidant [7-9]. Melatonin is an efficient 
protector of DNA [10], proteins and lipids in cellular membranes as 
well as antagonists of a number of endogenous and exogenous free 
radicals attack during cellular processes [11]. A wide range of action 
for this hormone makes it possible to use it in cancer therapy, 
Alzheimer’s disease, Parkinson’s disease and diabetes [12]. Many 
authors have also examined the prophylactic effect of melatonin in 
reducing lead-induced toxicity [13]. Based on the antioxidant effect 
of melatonin, we aimed to investigate the chelating effect as well as 
the ameliorating effect of melatonin on certain biochemical 
alterations associated with iron overload-induced toxicity in rats. 
MATERIALS AND METHODS 
Chemicals 
All used chemicals were of the highest quality available and 
purchased from Sigma Chemical Co., USA. Reagent Kits used for 
determination of iron and total iron binding capacity were obtained 
from Stanbio Laboratories, Italy. Reagent Kit used for determination 
of transferrin (RSCPRG091R) was manufactured by Bio Vendor 
Research and Diagnostic Products, Heidelberg, Germany. All other 
reagent kits were purchased from Bio-diagnostic Co., Egypt.  
Drug and antioxidant 
Elemental iron in the form of ferric hydroxide poly maltose complex 
was provided as “Haemojet ampoules”that produced by European 
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Egyptian Pharmaceutical. Ind. (EEPI), Alexandria, Egypt. Each 
ampoule of two ml solution contains elemental iron (100 mg). 
Induction of iron overload was carried out by intraperitoneal 
injections of ferric hydroxide polymaltose complex at a dose of 50 
mg/kg b. w (three doses per week) for 4 w [14]. Melatonin was 
purchased from Sigma Chemical Company, St. Louis, MO, USA. It 
dissolved in a minimum volume of ethanol (96%) and then diluted 
with distilled water (the final concentration of ethanol was less than 
0.5 %). Melatonin was daily injected subcutaneously at a dose of 10 
mg/kg body weight for 4 weeks [15]. 
Animals 
Twenty-four male albino rats (body weight 150-200 g) were 
obtained from the Animal House of the National Research Center, 
Dokki, Giza, Egypt. The rats were housed in plastic cages at an 
environmentally controlled room (constant temperature 25-27ºC, 
with 12 h light/dark cycle) for one week prior to starting the 
experiments, and they were provided with water and standard rat 
chow. Animal procedures were performed in accordance with the 
Guidelines for Ethical Conduct in the Care and Use of Animals.  
Experimental protocol 
After acclimatization, the animals were divided into 4 groups, 
consisting of 6 rats in each group. Group 1 (control): rats received 
0.5 ml of 0.01% ethanol subcutaneously (melatonin diluent) for four 
weeks. Group 2(iron overload): rats received intra peritoneal 
injection of ferric hydroxide polymaltose at a dose of 50 mg/kg body 
weight (three doses per week) for four weeks. Group 3 (melatonin): 
rats received the melatonin in ethanol subcutaneously (10 
mg/kg/day) for four weeks. Group 4(iron overload+melatonin): rats 
received ferric hydroxide polymaltose (as in group 2) and melatonin 
(as in group 3) for four weeks. The injection of melatonin was 30 
min before iron administration and was given 2 h before light off. 
Sample collection and tissue preparation  
At the end of the experimental period, the animals were fasted for 
16-18 hrs. before sacrificing. Animals were decapitated and blood 
was collected from each animal for separation of serum for different 
biochemical analysis. Portions of liver and kidney were stored at–80 
°C for iron assay. Portions of liver and kidney were immediately 
washed in ice-cold physiological saline and homogenized in 50 mM 
potassium phosphate (pH 7.4) to render 10% homogenate for 
different assays.  
Biochemical analysis 
Blood samples were centrifuged at 3000 rpm for 15 min. to separate 
serum. Estimation of serum iron and TIBC were carried out 
according to the methods described by Stookey [16] and Carter [17]. 
UIBC was calculated as UIBC =TIBC–iron. The serum TF% that 
indicate the level of iron supply to the tissues was determined as 
TF% = (Serum iron/TIBC) × 100. Serum transferrin was determined 
by enzyme-linked immunoassay using monoclonal antibodies [18]. 
Estimation of AST and ALT activities and total bilirubin were carried 
out using the methods of Reitman and Frankel [19] and Walters and 
Gerade [20] respectively. T. protein was analyzed in serum using the 
method of Lowry et al. [21]. Albumin was determined by the method 
of Doumaset al. [22]. Serum cholesterol and triglycerides were 
determined according to Allainet al. [23] &Fossati and Prencipe[24] 
methods respectively. Urea and creatinine concentrations were 
determined by the methods of Foster and Hochholzer [25] and 
Schirmeister et al. [26] respectively. Tissue homogenate was 
centrifuged at 10.000xg at 4 °C for 20 min. and the supernatant was 
used for analysis of MDA by Ohkawa et al .[27], CAT by Aebi [28], 
GPxby Paglia et al. [29] and GSH by Beutler et al. [30] methods. Total 
iron in liver and kidney tissues was measured using atomic 
absorption spectroscopy. Briefly, 0.1 g of tissue was weighed and 
placed in iron free glass tubes (washed with hydrochloric acid). The 
tissue was dried in an oven at 115 °C for 5 h, 0.3 ml of concentrated 
sulphuric acid was added and the samples were digested for 2 days. 
Subsequently,0.1 ml of concentrated nitric acid and 50 µl of 
hydrogen peroxide were added and the freed metal salts were 
determined using atomic absorption spectrophotometer (AAS, 
Perkin Elmer model A Analyst 100) at 248.3 nm. The results are 
expressed as μg Fe/g tissue [31]. MT was determined in liver and 
kidney tissues by cadmium saturation assay according to Onosaka 
and Cherian[32]. The concentration of MT in each tissue was 
calculated by assuming that 7 mol. of Cd are bound to 1 mol. of MT 
[33] and the levels of MT were expressed as μg MT/g tissue. 
Statistical analysis 
The results were expressed as mean±SE of studied groups using the 
analysis of variance test (one-way ANOVA) followed by Bonferroni 
test. Analysis was performed by statistical package for the social 
science software (SPSS Inc., Chicago, IL). Values of P<0.05 were 
considered significant. 
RESULTS 
Effect of melatonin on iron status in iron overloaded rats 
The serum iron concentration in iron overloaded rats was 
significantly (P<0.05) increased by 67% than that in control group. 
Simultaneously, TIBC, transferrin and TF% were increased(P<0.05) 
by 37%, 36 % and 33% respectively, while UIBC was significantly 
lower by 22% in iron overload rats than that in control group (table 
1). Treatment with melatonin (melatonin+iron overload group) 
significantly decreased serum iron, TIBC, transferrin and TF% by 
35%, 22%, 18% and 17% respectively.  
At the same time, melatonin elevated serum UIBC by 36% than those 
in iron overload rats (table 1). The iron significantly (P<0.05) tend to 
accumulated in the hepatic and renal tissues by 59% and 52%, 
respectively following iron overload than those in control group, 
while co-administration of melatonin with iron statistically (P<0.05) 
decreased iron concentration about 25% in liver and 23% in kidney 
as compared to iron overloaded rats. 
 
Table 1: Effect of melatonin on iron status of iron overloaded rats 
Groups parameters Control Iron overload Melatonin Iron overload+melatonin 
Serum iron(µg/dl) 141.27±7.17 235.36±11.76a 138.54±6.58b 152.17±6.84b 
TIBC(µg/dl) 215.73±4.98 295.03±2.80a 209.82±4.68b 231.54±4.25b 
UIBC(µg/dl) 75.10±2.91 58.94±2.70a 72.21±2.42b 80.19±4.58b 
Transferrin(g/l) 1.80±0.03 2.45±0.04a 1.85±0.04b 1.94±0.04b 
TS (%) 65.18±1.93 80.17±.2.19a 66.02±1.73b 66.32±2.66b 
Liver iron(µg/g) 200.32±10.2 318.60±14.5 192.40±9.7b 237.90±11.8a,b 
Kidney iron(µg/g) 135.31±6.4 205.27±10.4a 130.12±5.7b 157.50±6.3a,b 
Values are expressed as means±SE (n=6), a: significance difference as compared to control group at P<0.05 and b: significant difference as compared 
to iron overload group at P<0.05.  
 
Effect of melatonin on MDA and antioxidants in hepatic and 
renal tissues of iron overloaded rats 
As shown in table 2, iron overload significantly (P<0.05) increased 
the formation of MDA in the hepatic and renal tissues by 73% and 
105 % respectively as compared to control group. Co-administration 
of melatonin resulted in significant (P<0.05) reduction in MDA levels 
in both liver (30%) and kidney (23%) when compared with iron 
overload group. The results represented in table 2 also showed that 
in the iron overload group, there was a significantly (P<0.05) 
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decrease in hepatic and renal CAT activity (by 50 % and 52% 
respectively) and GPx activity (by 27% and 39% respectively) as 
well as GSH content (by 27% and 21% respectively) as compared to 
control group.  
Co-treatment with melatonin (iron overload+melatonin group) 
significantly (P<0.05) elevated the activities of CAT and GPx and the 
content of GSH in the hepatic and renal tissues as compared to iron 
overload group. 
 
Table 2: Effect of melatonin on MDA and antioxidants in hepatic and renal tissues of iron overloaded rats 





























































Values are expressed as means±SE (n=6), a: significance difference as compared to control group at P<0.05 and b: significant difference as compared 
to iron overload group at P<0.05.  
 
Effect of melatonin on liver and kidney functions in serum of 
iron overloaded rats 
As shown in table 3, significantly (P<0.05) increased levels of serum 
enzymes, ALT by 129% and AST by 49 % and total bilirubin by 118 
% in iron overload group, clearly signifies iron induced liver 
damage. Meanwhile, the levels of T. protein and albumin were 
significantly decreased by 36% and 35% respectively as compared 
to control group. The co-treatment of melatonin with iron displayed 
significant attenuation in these markers by reduction of ALT (76%), 
AST (20%) and bilirubin (36%) and elevation of T. protein and 
albumin by 42% and 50% respectively as compared to iron overload 
group returning them towards normal values. In addition, iron 
treatment (iron overload group) caused a significant increase 
(P<0.05) in the levels of cholesterol (42%) and triglycerides (50%) 
as compared to those of the control group. Co-treatment with 
melatonin led to significant (P<0.05) decrease in cholesterol and 
triglycerides levels by 22% and 24%, respectively as regard to iron 
overload group. Regarding renal functions, iron treatment produced 
about 112% and 73% enhancement in the values of serum 
creatinine and urea respectively, as compared with control group. 
Co-treatment with melatonin resulted in 43% and 37% reduction in 
the values of serum creatinine and urea respectively as compared 
with iron-treated group. 
 
Table 3: Effect of melatonin on liver and kidney functions in serum of iron overloaded rats 
Iron overload+melatonin Melatonin Iron overload Control Group parameter 
35.85±2.54a,b 21.83±1.49 b 46.71±4.20a 20.32±1.80 ALT(U/ml) 
78.15±3.04a. b 63.22±2.73 b 98.17±4.15a 65.80±3.54 AST(U/ml) 
1.59±0.13a,b 1.14±0.03 b 2.51±0.56a 1.15±0.05 Bilirubin(mg/dl) 
6.19±0.40b 6.51±0.43 b 4.35±0.21a 6.85±0.47 T. protein(g/dl) 
3.52±0.23b 3.65+0.22 b 2.34±0.14a 3.62±0.21 Albumin(g/dl) 
153.20±5.73a,b 132.14±6.12 b 196.37±6.31a 138.23±4.21 Cholesterol(mg/dl) 
132.30±4.69a,b 108.79±3.40 b 174.19±6.9a 115.81±3.71 Triglycerides(mg/dl) 
1.61±0.03a,b 1.17±0.05 b 2.49±0.04a 1.18±0.07 Creatinine(mg/dl) 
40.79±1.16a,b 34.96±1.04 b 61.83±2.50a 35.68±1.07 Urea(mg/dl) 
Values are expressed as means±SE (n=6), a: significance difference as compared to control group at P<0.05 and b: significant difference as compared 
to iron overload group at P<0.05.  
 
Effect of melatonin on MT in hepatic and renal tissues of iron 
overloaded rats  
Our results indicated that administration of iron alone resulted in 
the accumulation of MT in tissues; the level of MT was significantly 
(P<0.05) elevated by 117% and 158% in liver and kidney 
respectively as compared to control (Fig.1). On its own, melatonin 
significantly (p<0.05) increased the MT values in both liver and 
kidney by 70 % and 68% respectively. Co-administration of iron 
with melatonin resulted in an increase (P<0.05) in MT level in liver 
by 43% and kidney by 54% as compared to iron overload group 
while these values were increased by 212 % and 297% in liver in 
kidney respectively as regard to control group. 
DISCUSSION  
The transferrin, TIBC, UIBC, and TF% evaluate the blood's ability to 
bind and transport iron and are a reflection of iron stores. Evidence 
for iron toxicity in the current study was exhibited by the 
remarkable elevation of serum, liver and kidney iron concentrations, 
serum TIBC, transferrin and TS % in iron-overloaded rats, while 
serum UIBC was significantly decreased. Such increments were 
associated with exacerbated oxidative stress status and alterations 
of antioxidants. These results were in agreement with that recorded 
in several models of iron overload. Administration of ferric 
nitrilotriacetate was found to induced a significant deposition of iron 
in rat liver associated with oxidative stress [34], feeding rats with 
diets supplemented with ferric sulfate resulted in dose related 
increases in liver non-heme iron and lipid peroxidation [35] and 
injection of mice with iron dextran for 5 days exhibited an increased 
in liver iron deposition [36]. Regarding to renal tissue, Nematbakhsh 
et al. [37] described the deposition of iron in renal tissue of rats 
received iron dextran for a period of 4 weeks. Additionally, the 
results of the current study came in accordance with the data of 
Nahdi et al. [38] who stated that iron overload elicited an elevation 
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in serum and liver iron as well as TS%. Such alterations resulted in 
the presence of non-transferrin binding iron that catalyzing the 
formation of reactive radicals [39]. 
 
 
Fig. 1: Effect of melatonin on MT in hepatic and renal tissues of 
iron overloaded rats 
 
In the current study, the treatment of iron overloaded rats with 
melatonin reduced serum, hepatic and renal tissues iron 
concentration, serum TIBC, transferrin level and TS % while it 
elevated serum UIBC, thus supporting its iron chelating potency. 
Previously, Limson et al. [40] investigated the possible role of 
melatonin in metal regulation in the central nervous system using an 
electrothermal technique. The authors showed that melatonin 
formed complexes with several heavy metals including iron (III) not 
iron (II) and suggested that it removes iron (III) unbound to a 
protein, thus preventing it from reducing back to the form in which 
it generates free radicals via the Fenton reaction. Additionally, the 
hydrophilic and lipophilic nature of melatonin allows it freely moves 
across all cellular barriers facilitating the removal of toxic metals 
thus favoring the metal binding role of melatonin. However, the 
efficacy of melatonin is mainly attributed to its high lipophilicity 
[41]. It is well documented that the lipophilic agents are very 
effective in reducing toxic effects of heavy metals and their 
elimination from various organ systems [42, 43]. 
Moreover, in the present study, treatment of rats with ferric 
hydroxide poly maltose complex resulted in an elevation of MDA 
concentrations (as lipid peroxidation product) while GPx and CAT 
activities and GSH level were decreased in hepatic and renal tissues 
suggesting the increased utilization and subsequent depletion of 
these antioxidants to counter the increased level of lipid 
peroxidation. Similarly, in the previous studies, the treatment with 
ferric chloride, ferrous sulfate or iron dextran significantly increased 
lipid peroxidation product and reduced CAT activity and GSH 
content in mice and rat liver [44, 36]. On the other hand, ferric 
nitrilotriacetate administration induced significant alterations in 
renal oxidative/antioxidant status [45]. However, iron is a well-
known inducer of reactive oxygen species (ROS) and its ability to 
accelerate lipid peroxidation is well-established [46]. Iron overload 
can destruct the balance between pro oxidants and antioxidants, 
leading to sever loss of total antioxidant status level. Antioxidant 
enzymes such as CAT and GPx operate in concert with non-
enzymztic molecules such as GSH to contrast the ROS actions and to 
avoid oxidative damage [47].  
In the current study, administration of melatonin to iron overloaded 
rats significantly attenuated the increased levels of lipid 
peroxidation with concomitant improvement in the levels of liver 
and renal enzymatic and non-enzymatic antioxidant defenses. 
Melatonin was found to maintain the optimal fluidity of cellular 
membranes accomplished by reducing the peroxidation of inherent 
polyunsaturated fatty acids and indirectly reducing increased 
membrane rigidity [48] by positioning itself within cellular 
membranes to restrict damage to polyunsaturated fatty acids by 
toxic reactants [49]. Moreover, melatonin is considered as one of the 
most effective antioxidants where it exerts direct antioxidant effects 
via its free radical scavenging properties and/or by inhibiting their 
generation and exerts indirect antioxidant effects by stimulating 
antioxidant enzymes and inhibiting the activities of pro-oxidative 
enzymes [7].  
Furthermore, in the current study, iron overload caused many 
adverse effects including an elevation in the activities of ALT and 
AST and total bilirubin level as well as decreased contents of T. 
protein and albumin indicating liver injury. Such alterations could be 
attributed to the generation of ROS and oxidative damage by excess 
hepatic iron that may result in chronic necro-inflammatory diseases 
[50] and leakage of cellular enzymes into the blood stream due to 
the altered liver membrane permeability. The reduction of serum T. 
protein and albumin levels in the present work could be ascribed to 
changes in protein and free amino acids metabolism and their 
synthesis in injured liver cells and/or increased protein degradation. 
These disturbances in liver markers was in agreement with data 
described by Whittaker and Chanderbhan [51], Manjunatha and 
Srinivasan [52]who reported that iron-induced liver damage had 
been assessed by leakage of enzymes such as ALT and AST and 
lactate dehydrogenase into the blood. In addition, the decrease in T. 
protein and albumin were in accordance with those recorded 
previously, where the iron accumulation disrupts the cell redox 
balance and generates chronic oxidative stress, which damages DNA, 
lipids and protein in hepatocytes leading to both necrosis and 
apoptosis [53]. 
Additionally, in the present study, the significant increase of serum 
cholesterol and triglycerides in iron-overloaded animals are in line 
with similar finding reported by Whittaker and Chanderbhan [51] 
who found that serum cholesterol concentration increased directly 
followed iron supplementation and Sylvain et al. [54] who 
demonstrated a significant increase in triglycerides, free cholesterol 
and cholesteryl ester in iron overloaded rats. These alterations 
might be attributed to the marked membrane lipid peroxidation that 
considered with the cytotoxicity as an important factorin altering 
lipid metabolism [51] possibly by their effect on lipogenesis-related 
genes [55] and key enzymes for cholesterol homeostasis [56].  
In the current study, administration of melatonin to iron overloaded 
rats reduced the serum ALT and ALT activities as well as the total 
bilirubin, cholesterol and triglycerides concentrations and induced 
increases in serum T. protein and albumin, indicating its protective 
effect over liver and improvement in its functional efficiency. The 
hypocholesterolemic effect of exogenous melatonin might work 
through the augmentation of endogenous cholesterol clearance 
mechanisms [57]. Moreover, melatonin was found to have an 
extraordinary anti lipidemic effect [58].  
In the present work, elevated levels of urea and creatinine were 
observed in iron-overloaded rats, which were attenuated by the co-
treatment with melatonin. The disturbance of renal functions came 
similar to previous studies in which iron overload with ferric sulfate 
[35] or ferric nitrilotriacetate [45] exhibited high levels of urea and 
creatinine in rats. These increments in serum urea and creatinine 
could be attributed to the destruction and malfunction of kidney 
cells due to iron deposition.  
The current study indicated that iron administration alone resulted 
in the accumulation of MT in hepatic and renal tissues. These results 
are similar with that recorded by Yasutake and Hirayama [59] who 
demonstrated that feeding on the Fe-enriched diet brought about 
significant alterations of MT levels in both liver and kidney with 
concomitant Fe accumulation. Some investigators documented 
induction of hepatic MT after intra peritoneal injections of Fe in rats 
[60] and suggested that parenteral injection of iron would cause 
significant stress and, as such, promote MT biosynthesis [61]. In the 
current study, co-treatment of melatonin resulted in more increases 
in MT level in liver and kidney, thus giving more chelating effect on 
iron. The possible mechanisms of MT in protection against oxidative 
injury are due its capacity to bind heavy metals through the thiol 
group of its cysteine residues. It was found that MT serves in the 
management of essential divalent metal cations in many cell types 
through interfering with the toxic effects of xenobiotic, heavy metals 
and free radicals [62]. Furthermore, MT, a sulfhydryl–rich metal 
binding protein, may function in a manner similar to GSH. Where in 
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MT provides an intracellular ‘nucleophilic sink’ to trap free radicals, 
electrophiles and alky lasting agents [63, 64]. 
CONCLUSION 
In the present study, it could be concluded that melatonin is effective 
in amelioration the toxic effect of iron by chelating it, improvement of 
the iron profile, elevated the metal binding protein MT associated with 
the reduction of oxidative stress in liver and kidneys of male rats.  
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